Systemic light chain amyloidosis: an update for treating physicians
- 27 June 2013
- journal article
- Published by American Society of Hematology
- Vol. 121 (26), 5124-5130
- https://doi.org/10.1182/blood-2013-01-453001
Abstract
In immunoglobulin light chain amyloidosis a small, indolent plasma cell clone synthesizes light chains that cause devastating organ damage. Early diagnosis, based on prompt recognition of “red-flags” before advanced cardiomyopathy ensues, is essential for improving outcomes. Differentiation from other systemic amyloidoses may require advanced technologies. Prognosis depends on the extent of cardiac involvement, and cardiac biomarkers guide the choice of therapy. The protean clinical presentation requires individualized treatment. Close monitoring of clonal and organ response guides therapy changes and duration. Conventional or high-dose alkylator-based chemotherapy is effective in almost two-thirds of patients. Combinations of proteasome inhibitors, dexamethasone, and alkylators achieve high response rates, although controlled studies are needed. Risk-adapted stem cell transplant and consolidation with novel agents may be considered in selected patients. Immune-modulatory drugs are good options for refractory/relapsed patients. Novel agents and therapeutic targets are expected to be exploited, in an integrated, more effective and less toxic treatment strategy.Keywords
This publication has 78 references indexed in Scilit:
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisBlood, 2012
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialBlood, 2012
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisBlood, 2012
- Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsBlood, 2011
- Amyloidosis: Pathogenesis and New Therapeutic OptionsJournal of Clinical Oncology, 2011
- Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart FailureTransplantation, 2010
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010
- Kidney dysfunction during lenalidomide treatment for AL amyloidosisNephrology Dialysis Transplantation, 2010
- Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugsAmerican Journal of Hematology, 2010
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) AmyloidosisJournal of Clinical Oncology, 2010